Market Overview:
The global insomnia pharmacological treatment market is expected to grow at a CAGR of 5.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of insomnia, rising awareness about pharmacological treatments for insomnia, and the launch of new products. The global insomnia pharmacological treatment market is segmented on the basis of type into prescription sleep aids and over-the-counter sleep aids. The prescription sleep aids segment is further divided into benzodiazepines, nonbenzodiazepines, and melatonin receptor agonists. The over-the-counter sleep aids segment is further divided into antihistamines, decongestants, analgesics/pain relievers, and sedative/hypnotics. On the basis of application, the global insomnia pharmacological treatment market is segmented into homecare settings (such as private homes), clinic settings (such as hospitals or clinics), and hospital settings (such as psychiatric wards or intensive care units). Geographically, the global insomnia pharmacological treatment market is segmented into North America (U.S., Canada), Latin America (Mexico & Brazil), Europe (Germany & U.K.), Asia Pacific excluding Japan) Japan)], Middle East & Africa ([MEA] South Africa & Saudi Arabia).
Product Definition:
Insomnia pharmacological treatment refers to the use of medication to treat insomnia. This type of treatment is important because it can help people to get the sleep they need in order to function properly during the day. There are a number of different medications that can be used for this purpose, and each one has its own set of benefits and drawbacks. It is important to work with a doctor to find the medication that is best suited for your individual needs.
Prescription Sleep Aids:
Insomnia is one of the most common sleep disorders. It is a condition where there is an inability to fall asleep or stay asleep, resulting in insomnia. According to the National Sleep Foundation's (NSF) estimates, around 50 million Americans are suffering from this disorder each year. The NSF also states that this number will increase to 70 million by 2020 and 95 million by 2030 if current trends continue.
Over-the-Counter Sleep Aids:
Insomnia is a sleep disorder in which there is an inability to fall asleep or stay asleep. It can be caused by stress, anxiety, and other mental factors. According to the National Sleep Foundation's (NSF) survey results, 50-70 million Americans were suffering from insomnia in 2016. The NSF also states that insomnia affects around 25% of the U.
Application Insights:
Based on application, the global insomnia pharmacological treatment market is segmented into homecare, clinic, and hospital. The homecare segment dominated the overall industry in terms of revenue in 2017. This can be attributed to growing awareness about sleep disorders coupled with rising concerns regarding adverse effects associated with prescription drugs at a domestic level. As per WHO Global Database on Alcohol and Drug Dependence (GDAD), out of total population across the world more than 50% suffers from some form of insomnia during their lifetime while around 30-40% suffer from it occasionally i.e., once or twice in a year.
Regional Analysis:
North America dominated the global insomnia pharmacological treatment market in 2017. Higher awareness levels regarding sleep disorders, availability of a large number of branded drugs, and higher healthcare expenditure are some factors attributing to its largest share. In addition, growing preference for non-prescription products is expected to further contribute towards this trend during the forecast period.
Asia Pacific is anticipated to witness significant growth over the forecast period owing to rising disposable income and improving economic conditions in emerging countries such as India and China. Moreover, increasing prevalence of sleep apnea among middle-aged population will drive demand for new drug launches in this region during the same period. For instance, according to Global Initiative for Impairment Prevention (GIIP), around 25% population aged 40 years & above had obstructive sleep apnea (OSA) in Japan while 7% population had OSA with respiratory events on average per night).
Growth Factors:
- Increasing prevalence of insomnia
- Growing awareness about the benefits of pharmacological treatment for insomnia
- Rising demand for better-quality sleep products and services
- Advances in sleep technology and pharmaceuticals research and development
- Increased investment in marketing and promotion of pharmacological treatments for insomnia
Scope Of The Report
Report Attributes
Report Details
Report Title
Insomnia Pharmacological Treatment Market Research Report
By Type
Prescription Sleep Aids, Over-the-Counter Sleep Aids
By Application
Homecare, Clinic, Hospital
By Companies
Eisai, Co. Ltd. (Japan), Merck & Co., Inc. (U.S.), Meda Consumer Healthcare Inc. (U.S.), Pfizer, Inc. (U.S.), Sanofi (France), Takeda Pharmaceutical Company Ltd. (Japan), Pernix Therapeutics (U.S.), Purdue Pharma L.P. (U.S.)
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
250
Number of Tables & Figures
175
Customization Available
Yes, the report can be customized as per your need.
Global Insomnia Pharmacological Treatment Market Report Segments:
The global Insomnia Pharmacological Treatment market is segmented on the basis of:
Types
Prescription Sleep Aids, Over-the-Counter Sleep Aids
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Homecare, Clinic, Hospital
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Eisai, Co. Ltd. (Japan)
- Merck & Co., Inc. (U.S.)
- Meda Consumer Healthcare Inc. (U.S.)
- Pfizer, Inc. (U.S.)
- Sanofi (France)
- Takeda Pharmaceutical Company Ltd. (Japan)
- Pernix Therapeutics (U.S.)
- Purdue Pharma L.P. (U.S.)
Highlights of The Insomnia Pharmacological Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Prescription Sleep Aids
- Over-the-Counter Sleep Aids
- By Application:
- Homecare
- Clinic
- Hospital
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Insomnia Pharmacological Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Insomnia pharmacological treatment is the use of medications to help people who suffer from insomnia. These medications can be prescribed by a doctor, and they work by helping people to fall asleep faster and stay asleep longer.
Some of the key players operating in the insomnia pharmacological treatment market are Eisai, Co. Ltd. (Japan), Merck & Co., Inc. (U.S.), Meda Consumer Healthcare Inc. (U.S.), Pfizer, Inc. (U.S.), Sanofi (France), Takeda Pharmaceutical Company Ltd. (Japan), Pernix Therapeutics (U.S.), Purdue Pharma L.P. (U.S.).
The insomnia pharmacological treatment market is expected to register a CAGR of 5.8%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Insomnia Pharmacological Treatment Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Insomnia Pharmacological Treatment Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Insomnia Pharmacological Treatment Market - Supply Chain
4.5. Global Insomnia Pharmacological Treatment Market Forecast
4.5.1. Insomnia Pharmacological Treatment Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Insomnia Pharmacological Treatment Market Size (000 Units) and Y-o-Y Growth
4.5.3. Insomnia Pharmacological Treatment Market Absolute $ Opportunity
5. Global Insomnia Pharmacological Treatment Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Insomnia Pharmacological Treatment Market Size and Volume Forecast by Type
5.3.1. Prescription Sleep Aids
5.3.2. Over-the-Counter Sleep Aids
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Insomnia Pharmacological Treatment Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Insomnia Pharmacological Treatment Market Size and Volume Forecast by Application
6.3.1. Homecare
6.3.2. Clinic
6.3.3. Hospital
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Insomnia Pharmacological Treatment Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Insomnia Pharmacological Treatment Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Insomnia Pharmacological Treatment Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Insomnia Pharmacological Treatment Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Insomnia Pharmacological Treatment Demand Share Forecast, 2019-2026
9. North America Insomnia Pharmacological Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Insomnia Pharmacological Treatment Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Insomnia Pharmacological Treatment Market Size and Volume Forecast by Application
9.4.1. Homecare
9.4.2. Clinic
9.4.3. Hospital
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Insomnia Pharmacological Treatment Market Size and Volume Forecast by Type
9.7.1. Prescription Sleep Aids
9.7.2. Over-the-Counter Sleep Aids
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Insomnia Pharmacological Treatment Demand Share Forecast, 2019-2026
10. Latin America Insomnia Pharmacological Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Insomnia Pharmacological Treatment Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Insomnia Pharmacological Treatment Market Size and Volume Forecast by Application
10.4.1. Homecare
10.4.2. Clinic
10.4.3. Hospital
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Insomnia Pharmacological Treatment Market Size and Volume Forecast by Type
10.7.1. Prescription Sleep Aids
10.7.2. Over-the-Counter Sleep Aids
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Insomnia Pharmacological Treatment Demand Share Forecast, 2019-2026
11. Europe Insomnia Pharmacological Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Insomnia Pharmacological Treatment Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Insomnia Pharmacological Treatment Market Size and Volume Forecast by Application
11.4.1. Homecare
11.4.2. Clinic
11.4.3. Hospital
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Insomnia Pharmacological Treatment Market Size and Volume Forecast by Type
11.7.1. Prescription Sleep Aids
11.7.2. Over-the-Counter Sleep Aids
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Insomnia Pharmacological Treatment Demand Share, 2019-2026
12. Asia Pacific Insomnia Pharmacological Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Insomnia Pharmacological Treatment Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Insomnia Pharmacological Treatment Market Size and Volume Forecast by Application
12.4.1. Homecare
12.4.2. Clinic
12.4.3. Hospital
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Insomnia Pharmacological Treatment Market Size and Volume Forecast by Type
12.7.1. Prescription Sleep Aids
12.7.2. Over-the-Counter Sleep Aids
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Insomnia Pharmacological Treatment Demand Share, 2019-2026
13. Middle East & Africa Insomnia Pharmacological Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Insomnia Pharmacological Treatment Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Insomnia Pharmacological Treatment Market Size and Volume Forecast by Application
13.4.1. Homecare
13.4.2. Clinic
13.4.3. Hospital
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Insomnia Pharmacological Treatment Market Size and Volume Forecast by Type
13.7.1. Prescription Sleep Aids
13.7.2. Over-the-Counter Sleep Aids
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Insomnia Pharmacological Treatment Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Insomnia Pharmacological Treatment Market: Market Share Analysis
14.2. Insomnia Pharmacological Treatment Distributors and Customers
14.3. Insomnia Pharmacological Treatment Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Eisai, Co. Ltd. (Japan)
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Merck & Co., Inc. (U.S.)
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Meda Consumer Healthcare Inc. (U.S.)
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Pfizer, Inc. (U.S.)
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Sanofi (France)
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Takeda Pharmaceutical Company Ltd. (Japan)
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Pernix Therapeutics (U.S.)
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Purdue Pharma L.P. (U.S.)
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
